Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2014

View Archived Issues

Scientists develop probes to characterize cellular functions of DUB in humans

Novel claudin-targeting antibodies show potential antitumor and antiviral activity

MedImmune provides phase I results for anti-alpha toxin MAb

New periostin-targeting therapy for the treatment of choroidal FVM

Eisai presents highlights of fourth quarter of fiscal 2013

Researchers at Origenis prepare novel kinase inhibitors

Reckitt Benckiser enters into licensing agreement for arbaclofen placarbil

RaQualia, CiRA and iPS Academia Japan form research collaboration

Bayer HealthCare establishes research incubator in Berlin

Janssen Labs establishes South San Francisco biotechnology incubator

ZN-6168 demonstrates excellent safety and pharmacokinetic profile in animal studies

Astellas Pharma reviews recent activities from fourth quarter of fiscal 2013

NovelMed reports preclinical data on monoclonal antibody for osteoarthritis

Simeprevir in combination approved in the E.U. for HCV genotype 1 and 4 infection

GSK's TNF-R1-targeting antibody attenuates pulmonary inflammation

Almirall patent discloses PI3Kdelta inhibitors

Merck & Co. reports discovery of NS5B inhibitors

Roche divulges mGlu5 receptor modulators

Centrose receives federal grant for renal cancer research

InterMune provides Expanded Access Program for pirfenidone

Novartis receives complete response letter for RLX-030 for acute heart failure

Boston Scientific to acquire Bayer's Interventional Division

Chimerix regains rights to CMX-157

Pfizer plans NDA submission for palbociclib

PB-1046 given FDA orphan drug status for pulmonary hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...